Pharmaceutical Raw Materials

This product is a medicine used to treat conjunctivitis, trachoma and other eye infections.

Sulfamerazine is a kind of sulfanilamide antibacterial drug, which has similar effect to sulfadiazine, but it has high curative effect on the infection caused by hemolytic streptococcus and pneumococcus. Suitable for pneumonia, erysipelas, meningitis and other diseases. The absorption is fast and the toxicity is low.

Pazufloxacin is a kind of fluoroquinolones, which can inhibit the replication of bacterial DNA by inhibiting the activity of DNA helix topoisomerase IV. It is effective for general anaerobic bacteria, anaerobic gram positive bacteria and gram negative bacteria. It has strong antibacterial activity against Staphylococcus, enterobacter, Pseudomonas aeruginosa, various gram-negative bacteria, Bacteroides and Prevotella. This product has strong antibacterial activity against imipenem, cefazolin glycoside, ceftazidime resistant bacteria, intestinal bacterial flora, ampicillin resistant bacteria and Haemophilus influenzae. This product can kill Pseudomonas aeruginosa, Escherichia coli and Staphylococcus aureus. It is clinically used in respiratory tract, urinary tract, gynecology, surgery, otolaryngology, skin and soft tissue infections caused by sensitive bacteria.

Lomidixin is a histone deacetylase inhibitor, which can control the growth and induce apoptosis in neuroblastoma cells.

Kabalatin tartrate is the tartrate of kabalatin for Alzheimer's disease. Kabalatin is a derivative of physostigmine, which was developed by Novartis for the first time. The molecule has a phenyl carbamate structure. It is a carbamate brain selective cholinesterase inhibitor, which can inhibit acetylcholinesterase and butyrylcholinesterase at the same time, By delaying the degradation of acetylcholine released by cholinergic neurons and promoting cholinergic nerve conduction, we can improve the cognitive dysfunction mediated by cholinergic neurons, so as to improve the cognitive function of patients with Alzheimer's disease. The plasma protein binding capacity of kabalatine is weak, and it is easy to pass through the blood-brain barrier, so it has high brain selectivity. It can not only selectively affect the most vulnerable cerebral cortex and hippocampus, but also preferentially inhibit the dominant subtypes of ache in the brain, which can produce curative effect and reduce the peripheral cholinergic side effects. The half-life of cabalatine tartrate in vivo is short and the action time is long. Different from tacrine, this product has stronger inhibitory effect on G1 enzyme in hippocampus and cortex. Clinically, it is used for the treatment of mild and moderate Alzheimer's dementia, that is, suspected Alzheimer's disease or Alzheimer's disease.